Ensysce Biosciences Inc., a clinical-stage pharmaceutical company, has announced the commencement of a pivotal Phase 3 study for its lead product candidate, PF614. This next-generation opioid is designed to provide effective pain relief while minimizing the risk of abuse. The study, titled PF614-301, is a multicenter, randomized, double-blind, placebo- and active-controlled trial aimed at evaluating the efficacy and safety of PF614 in treating moderate to severe pain following abdominoplasty surgery. Ensysce has partnered with Rho, Inc., a Clinical Research Organization with expertise in CNS disorders and pain studies, to conduct this trial. The results of this study are yet to be presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1049119) on July 16, 2025, and is solely responsible for the information contained therein.